Quantcast
Home > Quotes > UTHR
UTHR

United Therapeutics Corporation Common Stock (UTHR) Quote & Summary Data

$116.52
*  
4.97
4.09%
Get UTHR Alerts
*Delayed - data as of Nov. 19, 2018  -  Find a broker to begin trading UTHR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    UTHR Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
111.5
Today's High / Low
$ 122.37 / $ 115.765
Share Volume
480,531
50 Day Avg. Daily Volume
361,323
Previous Close
$ 121.49
52 Week High / Low
$ 152.55 / $ 100.57
Market Cap
5,078,777,981
P/E Ratio
9.4
Forward P/E (1y)
8.16
Earnings Per Share (EPS)
$ 12.40
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.96

Intraday Chart

Shares Traded

Share Volume:
480,531
50 Day Avg. Daily Volume:
361,323

P/E Ratio

P/E Ratio:
9.4
Forward P/E (1y):
8.16
Earnings Per Share (EPS):
$ 12.40

Trading Range

The current last sale of $116.52 is 15.86% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 122.37 $ 152.55
 Low: $ 115.765 $ 100.57

ETFs with UTHR as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
384% ALPS Medical Breakthroughs ETF (SBIO) -4.50 (-12.21%)
2.36% First Trust Health Care AlphaDEX (FXH) -0.63 (-0.85%)
0.73% WisdomTree U.S. MidCap Earnings Fund (EZM) -2.34 (-5.83%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. We market and sell four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin® (treprostinil) Injection (Remodulin); Tyvaso® (treprostinil) Inhalation Solution (Tyvaso); Orenitram® (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca® (tadalafil) Tablets (Adcirca). We also market and sell an oncology product in the United States, Unituxin® (dinutuximab) Injection (Unituxin), which is approved for treatment of high-risk neuroblastoma. Outside the United States, our only significant revenues are derived from the sale of Remodulin, which is approved in Europe and various other countries.  ... More ...  


Risk Grade

Where does UTHR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 121.49
Open Date:
Nov. 19, 2018
Close Price:
$ 116.52
Close Date:
Nov. 19, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x